



September 10, 2009

To those concerned

R-Tech Ueno, Ltd.
(Code No.4573, Osaka Securities Exchange; Hercules)
Head Office: 1-1-7 Uchisaiwai-cho, Chiyoda-ku, Tokyo
Representative: Yukihiro Mashima,
Representative Director & President
Contact: Koji Nakamura,
Business Management Department;
TEL: +81-3-(3596) 8011

Notification of Establishment of Medical Advisory Board

Purpose

The pharmaceutical industry in Japan is entering a period of enormous changes. Major events include government measures to cut health care expenses, reductions in national health insurance drug prices, the upcoming patent expirations of many major drugs (the so-called “2010 problem”), and government’s policy of increasing the use of generic drugs. Pharmaceutical companies in Japan are all responding in their own ways in order to survive in this difficult environment. One result is the division of pharmaceutical companies into different categories. As the process takes place, R-Tech Ueno, Ltd. has established the goal of becoming “a global pharmaceutical company specializing in the development and sale of ophthalmology and dermatology drugs from the viewpoint of physicians.”

Pharmaceutical companies sell drugs to physicians, but patients are the beneficiaries of these drugs. Medical affairs activities (see note below) are vital to responding swiftly to the dramatic shifts in the health care and social environments involving the use of drugs. These activities use the experience of physicians who prescribe drugs for the purpose of meeting the needs of physicians who make decisions concerning how to prescribe drugs for their patients.

Due to the importance it places on medical affairs, R-Tech Ueno has decided to establish a Medical Advisory Board. The board will serve as an advisory body to the R-Tech Ueno Executive Committee, which is overseen by the company president, who is a physician. Members of the board are physicians and other specialists in the field of ophthalmology. By focusing on specific themes, they will be asked to discuss from many perspectives problems involving ophthalmology care and the future direction of health care in this field. Opinions and suggestions provided by the Medical Advisory Board will be used to conduct pharmaceutical business operations more effectively. R-Tech Ueno will also distribute this information to health care professionals in the ophthalmology field. In addition, R-Tech

Ueno will ask board members to evaluate the company's performance once each year from the standpoint of physicians.

The 10 Members of the R-Tech Ueno Medical Advisory Board

- Glaucoma

Dr. Kazuhisa Sugiyama

Professor, Department of Ophthalmology & Visual Science, Graduate School of Medical Science, Kanazawa University

Dr. Goji Tomita

Professor, 2nd Department of Ophthalmology, School of Medicine, Faculty of Medicine, Toho University

- Vitreoretinal disease

Dr. Yozo Miyake (Chairman)

Professor Emeritus, Department of Ophthalmology, Graduate School of Medicine, Nagoya University

Dr. Akito Hirakata

Professor, Department of Ophthalmology, Faculty of Medicine, Kyorin University

Dr. Taiji Sakamoto

Professor, Department of Ophthalmology, Faculty of Medicine, Kagoshima University

- Cataracts

Dr. Daijiro Kurosaka

Professor, Department of Ophthalmology, Faculty of Medicine, Iwate Medical University

- Keratoconjunctivitis

Dr. Teruo Nishida

Professor, Department of Ophthalmology, Graduate School of Medicine, Yamaguchi University

- Neuro-ophthalmology

Dr. Yoshihisa Oguchi

Professor Emeritus, Department of Ophthalmology, School of Medicine, Keio University

- Ophthalmologists

Dr. Hidenao Ideta

Director Emeritus, Ideta Eye Hospital

Dr. Kenji Inoue

President, Inoue Eye Hospital

Note :

Medical affairs

Medical affairs activities use the experience of physicians who prescribe drugs. The purpose is to accurately reflect the needs of physicians concerning how to prescribe drugs for their patients in a company's drug development operations and marketing strategies. Recently, an increasing number of major European and U.S. pharmaceutical companies have established medical affairs units made up of physicians. Furthermore, in Japan, The Japanese Association of Pharmaceutical Medicine (<http://japhmed.jp>) has been established by physicians who are employed by pharmaceutical companies. By conducting a variety of activities associated with the development of drugs, this association seeks to contribute to improvements in health care.